Burlington-based LabCorp has developed the first testing method to simultaneously detect for COVID-19, influenza A / B, and respiratory syncytial virus (RSV) just in time for the upcoming flu season.
ColoSense is designed for adults aged 45 to 85 years who are considered at average risk for colorectal cancer.